MagicTouch SCB receives IDE approval for In-Stent Restenosis indication

PRNewswire September 19, 2022

TAMPA, Fla., Sept. 19, 2022 /PRNewswire/ –┬áThe US FDA has granted an Investigational Device Exemption (IDE) approval for MagicTouch┬áSirolimus Coated Balloon (SCB) indicated for In-Stent Restenosis (ISR).

World's first IDE approved Sirolimus Coated Balloon in Coronary - MagicTouch SCB

US FDA’s IDE approval allows the MagicTouch SCB to be used in a pivotal clinical study to support safety and effectiveness of this combination product. The data generated from this IDE clinical study will support a pre-market approval (PMA) application in the USA.

MagicTouch SCB is the world’s first Sirolimus-coated Balloon with extensive commercial usage in Europe, major markets of Asia and the Mid-Eastern markets. More than 100 thousand patients have been treated with MagicTouch SCB in these markets.

About MagicTouch SCB:

MagicTouch SCB is a CE marked and commercially marketed Sirolimus coated balloon developed by Concept Medical, using proprietary Nanolut├® Technology. MagicTouch SCB has been used in >50,000 patients in major global markets.

About Concept Medical Inc (CMI):

CMI is headquartered in Tampa, Florida and has operational offices in The Netherlands, Singapore and Brazil and manufacturing units in India. CMI specializes in developing drug-delivery systems and has unique and patented technology platforms that can be deployed to deliver any drug / pharmaceutical agent across the luminal surfaces of blood vessels.

Concept Medical Logo


SOURCE Concept Medical

AAPR aggregates press releases and media statements from around the world to assist our news partners with identifying and creating timely and relevant news.

All of the press releases published on this website are third-party content and AAP was not involved in the creation of it. Read the full terms.